OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Cancers & treatments·Sequencing

NTRK fusion-positive non-small-cell lung cancer: lines of therapy

Cancer page →

1 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Second line1

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, first line or after chemotherapyLarotrectinib or entrectinib under their tumour-agnostic approvals; repotrectinib after resistance to either; chemoimmunotherapy as for driver-negative disease before or after.
LarotrectinibNAVIGATEEntrectinibBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene RearrangemeRepotrectinibTumour-agnostic (tissue-agnostic) approvalPembrolizumabCarboplatinPemetrexed
98

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.